Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2020

19.12.2019 | Original Article

FDG-PET assessment and metabolic patterns in Lafora disease

verfasst von: Lorenzo Muccioli, Andrea Farolfi, Federica Pondrelli, Giuseppe d’Orsi, Roberto Michelucci, Elena Freri, Laura Canafoglia, Laura Licchetta, Francesco Toni, Rachele Bonfiglioli, Simona Civollani, Cinzia Pettinato, Elisa Maietti, Giorgio Marotta, Stefano Fanti, Paolo Tinuper, Francesca Bisulli

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe cerebral glucose metabolism pattern as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in Lafora disease (LD), a rare, lethal form of progressive myoclonus epilepsy caused by biallelic mutations in EPM2A or NHLRC1.

Methods

We retrospectively included patients with genetically confirmed LD who underwent FDG-PET scan referred to three Italian epilepsy centers. FDG-PET images were evaluated both visually and using SPM12 software. Subgroup analysis was performed on the basis of genetic and clinical features employing SPM. Moreover, we performed a systematic literature review of LD cases that underwent FDG-PET assessment.

Results

Eight Italian patients (3M/5F, 3 EPM2A/5 NHLRC1) underwent FDG-PET examination after a mean of 6 years from disease onset (range 1–12 years). All patients showed bilateral hypometabolic areas, more diffuse and pronounced in advanced disease stages. Most frequently, the hypometabolic regions were the temporal (8/8), parietal (7/8), and frontal lobes (7/8), as well as the thalamus (6/8). In three cases, the FDG-PET repeated after a mean of 17 months (range 7–36 months) showed a metabolic worsening compared with the baseline examination. The SPM subgroup analysis found no significant differences based on genetics, whereas it showed a more significant temporoparietal hypometabolism in patients with visual symptoms compared with those without. In nine additional cases identified from eight publications, FDG-PET showed heterogeneous findings, ranging from diffusely decreased cerebral glucose metabolism to unremarkable examinations in two cases.

Conclusions

FDG-PET seems highly sensitive to evaluate LD at any stage and may correlate with disease progression. Areas of decreased glucose metabolism in LD are extensive, often involving multiple cortical and subcortical regions, with thalamus, temporal, frontal, and parietal lobes being the most severely affected. Prospective longitudinal collaborative studies are needed to validate our findings.
Literatur
1.
Zurück zum Zitat Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease – from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14:606–17.CrossRef Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease – from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14:606–17.CrossRef
2.
Zurück zum Zitat Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat. 2009;30:715–23.CrossRef Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat. 2009;30:715–23.CrossRef
3.
Zurück zum Zitat Drury I, Blaivas M, Abou-Khalil BW, Beydoun A. Biopsy results in a kindred with Lafora disease. Arch Neurol. 1993;50:102–5.CrossRef Drury I, Blaivas M, Abou-Khalil BW, Beydoun A. Biopsy results in a kindred with Lafora disease. Arch Neurol. 1993;50:102–5.CrossRef
4.
Zurück zum Zitat Villanueva V, Linera JA, Gòmez-Garre P, Gutiérrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia. 2006;47:788–92.CrossRef Villanueva V, Linera JA, Gòmez-Garre P, Gutiérrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia. 2006;47:788–92.CrossRef
5.
Zurück zum Zitat Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Disord. 2016;18:38–62.CrossRef Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Disord. 2016;18:38–62.CrossRef
6.
Zurück zum Zitat Jennesson M, Milh M, Villeneuve N, et al. Posterior glucose hypometabolism in Lafora disease: early and late FDG-PET assessment. Epilepsia. 2010;51:708–11.CrossRef Jennesson M, Milh M, Villeneuve N, et al. Posterior glucose hypometabolism in Lafora disease: early and late FDG-PET assessment. Epilepsia. 2010;51:708–11.CrossRef
7.
Zurück zum Zitat Kato Z, Yasuda K, Ishii K, et al. Glucose metabolism evaluated by positron emission tomography in Lafora disease. Pediatr Int. 1999;41:689–92.CrossRef Kato Z, Yasuda K, Ishii K, et al. Glucose metabolism evaluated by positron emission tomography in Lafora disease. Pediatr Int. 1999;41:689–92.CrossRef
8.
Zurück zum Zitat Tsuda H, Katsumi Y, Nakamura M, et al. Cerebral blood flow and metabolism in Lafora disease. Rinsho Shinkeigaku. 1995;35:175–9.PubMed Tsuda H, Katsumi Y, Nakamura M, et al. Cerebral blood flow and metabolism in Lafora disease. Rinsho Shinkeigaku. 1995;35:175–9.PubMed
9.
Zurück zum Zitat Al Otaibi SF, Minassian BA, Ackerley CA, Logan WJ, Weiss S. Unusual presentation of Lafora’s disease. J Child Neurol. 2003;18:499–501.CrossRef Al Otaibi SF, Minassian BA, Ackerley CA, Logan WJ, Weiss S. Unusual presentation of Lafora’s disease. J Child Neurol. 2003;18:499–501.CrossRef
10.
Zurück zum Zitat Casciato S, Gambardella S, Mascia A, et al. Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: a case report. Int J Neurosci. 2017;127:1150–3.CrossRef Casciato S, Gambardella S, Mascia A, et al. Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: a case report. Int J Neurosci. 2017;127:1150–3.CrossRef
11.
Zurück zum Zitat Cohen AL, Jones LK, Parisi JE, Klaas JP. Intractable epilepsy and progressive cognitive decline in a young man. JAMA Neurol. 2017;74:737–40.CrossRef Cohen AL, Jones LK, Parisi JE, Klaas JP. Intractable epilepsy and progressive cognitive decline in a young man. JAMA Neurol. 2017;74:737–40.CrossRef
12.
Zurück zum Zitat Driver-Dunkley E, Sirven J, Drazkowski J, Caviness JN. Lafora disease with primary generalized epileptic myoclonus. Mov Disord. 2005;20:907–8.CrossRef Driver-Dunkley E, Sirven J, Drazkowski J, Caviness JN. Lafora disease with primary generalized epileptic myoclonus. Mov Disord. 2005;20:907–8.CrossRef
13.
Zurück zum Zitat Shandal V, Veenstra AL, Behen M, Sundaram S, Chugani H. Long-term outcome in children with intractable epilepsy showing bilateral diffuse cortical glucose hypometabolism pattern on positron emission tomography. J Child Neurol. 2012;27:39–45.CrossRef Shandal V, Veenstra AL, Behen M, Sundaram S, Chugani H. Long-term outcome in children with intractable epilepsy showing bilateral diffuse cortical glucose hypometabolism pattern on positron emission tomography. J Child Neurol. 2012;27:39–45.CrossRef
14.
Zurück zum Zitat Franceschetti S, Gambardella A, Canafoglia L, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia. 2006;47:640–3.CrossRef Franceschetti S, Gambardella A, Canafoglia L, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia. 2006;47:640–3.CrossRef
15.
Zurück zum Zitat Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–010.CrossRef Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–010.CrossRef
16.
Zurück zum Zitat Friston KJ, Passingham RE, Nutt JG, Heather JD, Sawle GV, Frackowiak RS. Localisation in PET images: direct fitting of the intercommissural (AC-PC) line. J Cereb Blood Flow Metab. 1989;9(5):690–5.CrossRef Friston KJ, Passingham RE, Nutt JG, Heather JD, Sawle GV, Frackowiak RS. Localisation in PET images: direct fitting of the intercommissural (AC-PC) line. J Cereb Blood Flow Metab. 1989;9(5):690–5.CrossRef
17.
Zurück zum Zitat Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25(7):663–7.PubMed Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25(7):663–7.PubMed
18.
Zurück zum Zitat Van Heycop Ten Ham MW, De Jager H. Progressive myoclonus epilepsy with Lafora bodies. Clinico-pathological features. Epilepsia 1963;4:95–119. Van Heycop Ten Ham MW, De Jager H. Progressive myoclonus epilepsy with Lafora bodies. Clinico-pathological features. Epilepsia 1963;4:95–119.
19.
Zurück zum Zitat Schwarz GA, Yanoff M, et al. Lafora’s disease. Distinct clinico-pathologic form of Unverricht’s syndrome. Arch Neurol. 1965;12:172–88.CrossRef Schwarz GA, Yanoff M, et al. Lafora’s disease. Distinct clinico-pathologic form of Unverricht’s syndrome. Arch Neurol. 1965;12:172–88.CrossRef
20.
Zurück zum Zitat Traoré M, Landouré G, Motley W, et al. Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease. Neurogenetics. 2009;10:319–23.CrossRef Traoré M, Landouré G, Motley W, et al. Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease. Neurogenetics. 2009;10:319–23.CrossRef
21.
Zurück zum Zitat Sokoloff L. The deoxyglucose method for the measurement of local glucose utilization and the mapping of local functional activity in the central nervous system. Int Rev Neurobiol. 1981;22:287–333.CrossRef Sokoloff L. The deoxyglucose method for the measurement of local glucose utilization and the mapping of local functional activity in the central nervous system. Int Rev Neurobiol. 1981;22:287–333.CrossRef
22.
Zurück zum Zitat Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–91.CrossRef Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–91.CrossRef
23.
Zurück zum Zitat Ganesh S, Delgado-Escueta AV, Sakamoto T. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002;11:1251–62.CrossRef Ganesh S, Delgado-Escueta AV, Sakamoto T. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002;11:1251–62.CrossRef
24.
Zurück zum Zitat De Volder AG, Cirelli S, de Barsy T, et al. Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET. J Neurol Neurosurg Psychiatry 1990;52:1063–1067. De Volder AG, Cirelli S, de Barsy T, et al. Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET. J Neurol Neurosurg Psychiatry 1990;52:1063–1067.
25.
Zurück zum Zitat Sperling MR, Gur RC, Alavi A, et al. Subcortical metabolic alterations in partial epilepsy. Epilepsia. 1990;31:145–55.CrossRef Sperling MR, Gur RC, Alavi A, et al. Subcortical metabolic alterations in partial epilepsy. Epilepsia. 1990;31:145–55.CrossRef
26.
Zurück zum Zitat Benedek K, Juhàsz C, Muzik O, et al. Metabolic changes of subcortical structures in intractable focal epilepsy. Epilepsia. 2004;45:1100–5.CrossRef Benedek K, Juhàsz C, Muzik O, et al. Metabolic changes of subcortical structures in intractable focal epilepsy. Epilepsia. 2004;45:1100–5.CrossRef
27.
Zurück zum Zitat Newberg AB, Alavi A, Berlin J, et al. Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures. J Nucl Med. 2000;41:1964–8.PubMed Newberg AB, Alavi A, Berlin J, et al. Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures. J Nucl Med. 2000;41:1964–8.PubMed
28.
Zurück zum Zitat Agarwal R, Humar A, Tiwari VN, Chugani H. Thalamic abnormalities in children with continuous spike-wave during slow-wave sleep: an F-18-fluorodeoxyglucose positron emission tomography perspective. Epilepsia. 2016;57:263–71.CrossRef Agarwal R, Humar A, Tiwari VN, Chugani H. Thalamic abnormalities in children with continuous spike-wave during slow-wave sleep: an F-18-fluorodeoxyglucose positron emission tomography perspective. Epilepsia. 2016;57:263–71.CrossRef
29.
Zurück zum Zitat Kim JH, Im KC, Kim JS, Lee SA, Kang JK. Correlation of interictal spike-wave with thalamic glucose metabolism in juvenile myoclonic epilepsy. Neuroreport. 2005;16:1151–5.CrossRef Kim JH, Im KC, Kim JS, Lee SA, Kang JK. Correlation of interictal spike-wave with thalamic glucose metabolism in juvenile myoclonic epilepsy. Neuroreport. 2005;16:1151–5.CrossRef
30.
Zurück zum Zitat Pichiecchio A, Veggiotti P, Cardinali S, et al. Lafora disease: spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol. 2008;12:342–7.CrossRef Pichiecchio A, Veggiotti P, Cardinali S, et al. Lafora disease: spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol. 2008;12:342–7.CrossRef
31.
Zurück zum Zitat Andrade DM, del Campo JM, Moro E, Minassian BA, Wennberg RA. Nonepileptic visual hallucinations in Lafora disease. Neurology. 2005;64:1311–2.CrossRef Andrade DM, del Campo JM, Moro E, Minassian BA, Wennberg RA. Nonepileptic visual hallucinations in Lafora disease. Neurology. 2005;64:1311–2.CrossRef
32.
Zurück zum Zitat Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8:433–44.CrossRef Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8:433–44.CrossRef
33.
Zurück zum Zitat Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5:331–42.CrossRef Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5:331–42.CrossRef
34.
Zurück zum Zitat Sullivan MA, Nitschke S, Steup M, Minassian BA, Nitschke F. Pathogenesis of Lafora disease: transition of soluble glycogen to insoluble polyglucosan. Int J Mol Sci. 2017;18. Sullivan MA, Nitschke S, Steup M, Minassian BA, Nitschke F. Pathogenesis of Lafora disease: transition of soluble glycogen to insoluble polyglucosan. Int J Mol Sci. 2017;18.
35.
Zurück zum Zitat Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22:487–97.CrossRef Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22:487–97.CrossRef
36.
Zurück zum Zitat Van Bogaert P, Wikler D, Damhaut P, Hb S, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. Neuroimage. 1998;8:62–8.CrossRef Van Bogaert P, Wikler D, Damhaut P, Hb S, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. Neuroimage. 1998;8:62–8.CrossRef
37.
Zurück zum Zitat Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia. 1988;29(Suppl.2):S48–55.CrossRef Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia. 1988;29(Suppl.2):S48–55.CrossRef
38.
Zurück zum Zitat Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia. 1991;32:417–22.CrossRef Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia. 1991;32:417–22.CrossRef
Metadaten
Titel
FDG-PET assessment and metabolic patterns in Lafora disease
verfasst von
Lorenzo Muccioli
Andrea Farolfi
Federica Pondrelli
Giuseppe d’Orsi
Roberto Michelucci
Elena Freri
Laura Canafoglia
Laura Licchetta
Francesco Toni
Rachele Bonfiglioli
Simona Civollani
Cinzia Pettinato
Elisa Maietti
Giorgio Marotta
Stefano Fanti
Paolo Tinuper
Francesca Bisulli
Publikationsdatum
19.12.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04647-3

Weitere Artikel der Ausgabe 6/2020

European Journal of Nuclear Medicine and Molecular Imaging 6/2020 Zur Ausgabe